Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Immuneering (IMRX)
NASDAQ:IMRX
Immuneering (IMRX) Stock Price & Analysis
106 Followers
IMRX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.40 - $11.92
Previous Close$1.47
Volume295.78K
Average Volume (3M)708.25K
Market Cap
$43.59M
Enterprise Value-$37.61M
Total Cash (Recent Filing)$85.67M
Total Debt (Recent Filing)$4.46M
Price to Earnings (P/E)-0.8
Beta0.44
Next Earnings
May 07, 2024EPS Estimate
-$0.5Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.89
Shares Outstanding29,283,272
10 Day Avg. Volume434,778
30 Day Avg. Volume708,253
Standard Deviation0.40
R-Squared0.01
Alpha0.01
Financial Highlights & Ratios
Price to Book (P/B)0.52
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.90
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue-950.55
Enterprise Value/Gross Profit-10.00T>
Enterprise Value/Ebitda0.89
Forecast
1Y Price Target
$11.83Price Target Upside704.76% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering8
Immuneering News
Bulls Say, Bears Say
Bulls Say
Drug EfficacyPreclinical data showed that a triple combination of IMM-1-104, gemcitabine, and paclitaxel led to the strongest tumor volume reduction.
Safety ProfileIMM-1-104 showed an excellent safety and tolerability profile with no dose-limiting toxicities or serious treatment-related adverse events, potentially best-in-class.
Treatment PotentialTreatment with '104 suppressed expression of genes associated with chemotherapy resistance, which may enhance the efficacy of chemotherapy.
Bears Say
Clinical Trial ResultsIMM-1-104's lack of confirmed responses in Phase I raises concerns about its efficacy as a monotherapy.
Company OutlookWith operating expenses exceeding expectations, there are concerns about the company's cost management capabilities.
Financial PerformanceAnalyst lowers the price target to $8 due to revised, more conservative sales projections and market share estimates.
---
Ownership Overview
29.64% Insiders
17.72% Mutual Funds
7.10% Other Institutional Investors
45.55% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
IMRX FAQ
What was Immuneering’s price range in the past 12 months?
Immuneering lowest stock price was $1.40 and its highest was $11.92 in the past 12 months.
What is Immuneering’s market cap?
Currently, no data Available
When is Immuneering’s upcoming earnings report date?
Immuneering’s upcoming earnings report date is May 07, 2024 which is in 8 days.
How were Immuneering’s earnings last quarter?
Immuneering released its earnings results on Mar 01, 2024. The company reported -$0.52 earnings per share for the quarter, missing the consensus estimate of -$0.463 by -$0.057.
Is Immuneering overvalued?
According to Wall Street analysts Immuneering’s price is currently Undervalued.
Does Immuneering pay dividends?
Immuneering does not currently pay dividends.
What is Immuneering’s EPS estimate?
Immuneering’s EPS estimate is -$0.5.
How many shares outstanding does Immuneering have?
Immuneering has 29,653,355 shares outstanding.
What happened to Immuneering’s price movement after its last earnings report?
Immuneering reported an EPS of -$0.52 in its last earnings report, missing expectations of -$0.463. Following the earnings report the stock price went down -0.806%.
Which hedge fund is a major shareholder of Immuneering?
Among the largest hedge funds holding Immuneering’s share is Perceptive Advisors LLC. It holds Immuneering’s shares valued at N/A.
---
Immuneering Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$11.83 (704.76% Upside)
$11.83 (704.76% Upside)
Blogger Sentiment
Bullish
IMRX Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 681.1K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $3.4M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 1.3%
Last 30 Days ▲ 3.5%
Last 30 Days ▲ 3.5%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-86.64%
12-Months-Change
Fundamentals
Return on Equity
-53.36%
Trailing 12-Months
Asset Growth
-16.17%
Trailing 12-Months
Company Description
Immuneering
Immuneering Corpbiopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to leading pharmaceutical and biotechnology companies.
---
IMRX Stock 12 Months Forecast
Average Price Target
$11.83
▲(704.76% Upside)
Technical Analysis
Best Analysts Covering IMRX
1 Year
1 Year Success Rate
3/9 ratings generated profit
1 Year Average Return
-30.26%
reiterated a buy rating 2 months ago
Copying Geulah Livshits's trades and holding each position for 1 Year would result in 33.33% of your transactions generating a profit, with an average return of -30.26% per trade.
---